 | |
| Clinical data | |
|---|---|
| Routes of administration | By mouth[1] |
| Drug class | Antinicotinic |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C19H18F2N6O3 |
| Molar mass | 416.389 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
JNJ-39393406 is an experimental medication which is under development byJanssen Pharmaceutica, a division ofJohnson & Johnson, for the treatment ofdepressive disorders andsmoking withdrawal.[1] It acts as aselectivepositive allosteric modulator of theα7nicotinic acetylcholine receptor (nAChR).[1] It does not act on theα4β2 orα3β4 nAChRs or theserotonin5-HT3 receptor, and does not interact with a panel of 62 otherreceptors andenzymes.[2] The drug has been found to lower theagonist andnicotine threshold for activation of the α7 nAChR by 10- to 20-fold and to increase the maximum agonist response of the α7 nAChR by 17- to 20-fold.[2]
As of February 2018, JNJ-39393406 is inphase IIclinical trials for both depressive disorders and smoking withdrawal.[1] It was also under investigation for the treatment ofschizophrenia andAlzheimer's disease, but development for these indications was discontinued.[1]
 | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |
